Key result
ICDs, anti-arrhythmic drugs, and ablation primarily manage ventricular arrhythmias driving sudden cardiac death in HF.
Why the study?
Heart failure is increasingly prevalent and associated with ventricular arrhythmias, motivating a practical overview of current evidence on underlying pathophysiology, disease burden, and management strategies.
This review summarizes the pathophysiology, diagnosis, and management of ventricular arrhythmias in heart failure, emphasizing the role of ICDs, anti-arrhythmic drugs, and catheter ablation.
Supports standard ICD, drug, and ablation use in heart failure; leaves open comparative trials on optimized strategies.
Heart failure is an increasingly prevalent condition, which is associated with ventricular arrhythmias. The reduction in cardiac pumping efficiency leads to the activation of several compensatory mechanisms. These mechanisms eventually lead to cardiac remodelling and a decline in haemodynamic status, contributing to the formation of a substrate conducive to arrhythmias, including increased automaticity, triggered activity, and, most commonly, re-entry circuits. In turn, ventricular arrhythmias can lead to the worsening of heart failure. A diagnosis of heart failure and ventricular arrhythmias is obtained using the patient’s history, examination findings, and investigation results. A key tool in this is echocardiogram imaging, which visualises the cardiac chambers, determines ventricular ejection fraction, and identifies structural abnormalities. A reduction in ejection fraction is a significant risk factor for the development of ventricular arrhythmias. Arrhythmias are diagnosed by ECG, Holter monitoring, and telemetry or event monitoring, and should initially be treated by optimising the medical management of heart failure. Anti-arrhythmic drugs, including beta-blockers, are usually the first-line therapy. Sudden cardiac death is a significant cause of mortality in heart failure patients, and implantable cardioverter defibrillator devices are used in both primary and secondary prevention. Anti-arrhythmic drugs and catheter ablation are important adjunctives for minimising shock therapy. In addition, autonomic modulation may offer a novel method of controlling ventricular arrhythmias. The objective of this review is to provide a practical overview of this rapidly developing field in relation to current evidence regarding the underlying pathophysiology, burden of disease, and management strategies available.
No takes yet. Share an insight, caveat, or question.
Al-Hadithi et al. (2019) conducted a review in Congestive Heart Failure and Ventricular Arrhythmias. Implantable cardioverter defibrillators, anti-arrhythmic drugs, and catheter ablation was evaluated. Ventricular arrhythmias are a major cause of sudden cardiac death in heart failure patients, managed primarily through implantable cardioverter defibrillators, anti-arrhythmic drugs, and ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: